AptarGroup Acquires Majority Stake in Voluntis

Zentiva Completes Voluntary Public Purchase Offer for APONTIS PHARMA AG

December 9, 2024

Pharmaceuticals

Zentiva AG completed its voluntary public purchase offer for APONTIS PHARMA AG and now holds approximately 83.57% of the share capital and 85.27% of the voting rights. Under the investment agreement, APONTIS PHARMA's management board will seek to terminate trading of its shares on the Freiverkehr market immediately after settlement; Zentiva (a private-equity-backed pan‑European pharmaceutical platform) said this transaction supports its inorganic growth and portfolio expansion in cardiovascular medicines.

Volaris Group Acquires medaptus

November 17, 2020

Software

Volaris Group, an operating group of Constellation Software Inc., has acquired medaptus, a Boston-based healthcare IT software company. The acquisition expands Volaris’ healthcare software portfolio by adding medaptus’ revenue cycle, patient assignment, and throughput automation solutions to its vertical market offerings.

Polaris Private Equity Becomes Majority Investor in Valtus Group

February 19, 2026

Professional Services

Nordic private equity firm Polaris Private Equity has agreed to become the majority investor in Valtus Group, the France-headquartered executive interim management firm. The investment will support Valtus's international expansion and operational scaling while existing shareholders GENEO Capital Entrepreneur and Société Générale Capital Partenaires remain committed investors.

Innoviva Acquires Entasis Therapeutics

May 23, 2022

Biotechnology

Innoviva, Inc. agreed to acquire all outstanding shares of Entasis Therapeutics it did not already own for $2.20 per share in cash, valuing Entasis' equity at approximately $113 million on a fully diluted basis. The transaction makes Entasis a wholly owned subsidiary of Innoviva and advances Innoviva's strategy to expand into differentiated late-stage biopharmaceutical assets, including Entasis' lead antibacterial candidate SUL-DUR.

Catalyst Clinical Research Acquires Aptus Clinical

May 4, 2022

Healthcare Services

Catalyst Clinical Research, a portfolio company of NovaQuest Capital Management, has acquired U.K.-based Aptus Clinical to accelerate Catalyst's European expansion and broaden its oncology and early-phase clinical services. The deal creates a multi-region CRO operating across North America and Europe, increases Catalyst's patient reach by nearly 600 and lifts combined headcount to more than 800.

Qvantel Acquires Optiva Inc.

December 31, 2025

Software

Qvantel Oy completed its acquisition of Optiva Inc. via a statutory plan of arrangement, acquiring all issued and outstanding common shares of Optiva. The transaction paid Optiva shareholders C$0.25 per common share, cancelled Optiva's US$108.6 million PIK notes with consideration to noteholders (including purchaser shares, purchaser-issued senior secured notes and warrants), and will result in Optiva being dissolved and delisted from the Toronto Stock Exchange. The combined company expands Qvantel's telecom monetization and digital operations portfolio and supports more than 70 operators with a global workforce exceeding 1,000 professionals.